Article Abstract

Evaluating “treatment as prevention” on the road to hepatitis C virus elimination

Authors: Sema Nickbakhsh, John McLauchlan, E. Carol McWilliam Leitch


Fraser and colleagues (1) have recently published the results of a study modelling the direct acting antiviral (DAA) scale-up requirements needed to reduce hepatitis C virus (HCV) infection in people who inject drugs (PWID) within selected European sites. Such “treatment as prevention” strategies have been previously proposed to address the ambitious WHO HCV elimination target for 2030 (2), established in response to the world-wide exponential growth in HCV-associated liver disease which has occurred in the past few decades and is a leading cause of increased liver-related mortality (3).